MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:36Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Topical antibiotics]]
			[[Category:Antibacterials]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #171

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #171

New page

{{MedTemplate
| generic = Mupirocin
| brand = Bactroban, Centany
| structure =
| classes = [[:Category:Topical_antibiotics|Topical antibiotic]], [[:Category:Antibacterials|Antibacterial]]
| uses = <vote slug="impetigo-use">Impetigo</vote>, <vote slug="ssti-localized-use">Localized superficial skin infections (folliculitis, secondarily infected dermatitis)</vote>, <vote slug="mrsa-decolonization-use">MRSA nasal decolonization (pre-operative or institutional outbreaks)</vote>
| starting_dose = Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days
| preparations = 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal)
| fda_max = Limit topical to 10-day courses to reduce resistance pressure
| pill_id =
| routes = Topical, intranasal
| onset = Days
| duration = Hours per application
| halflife = Not meaningfully described for topical use<ref name="bactroban-label">FDA Prescribing Information, Bactroban (mupirocin), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050591s029,050595s022lbl.pdf</ref>
| bioavailability = Topical; minimal systemic absorption<ref name="bactroban-label" />
| pregnancy = Generally considered safe; minimal systemic exposure.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="mupirocin-mech-claim">Mupirocin (pseudomonic acid A) binds bacterial isoleucyl-tRNA synthetase, blocking incorporation of isoleucine into bacterial proteins and arresting protein synthesis; the human counterpart enzyme is sufficiently different that there is no cross-reactivity.</vote> Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use<ref name="bactroban-label" />.
}}

== References ==
<references />

Mupirocin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #171